Answers are grounded in this paper and cite their sources.
Systematic review and network meta-analysis reveal therapy impacts progression-free and overall survival in newly diagnosed multiple myeloma patients.
We performed a comprehensive review with meta‐ and network meta‐analyzes of maintenance‐therapy studies. Lenalidomide, proteasome inhibitors, and CD38 antibodies improved progression‐free survival (PFS). However, overall survival (OS) benefit appeared only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS not seen with proteasome inhibitors. The network meta‐analysis ranked regimens against observation: daratumumab–lenalidomide (DR) yielded the greatest PFS benefit, followed by carfilzomib–lenalidomide–dexamethasone (KRd), KR in TE, and DRd in transplant‐ineligible patients. Significant OS prolongation in TE patients occurred with KR, DR, and lenalidomide alone.
No takes yet. Share an insight, caveat, or question.
Ludwig et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: